Buprenorphine, Methadone, and the Adolescent OUD Treatment Gap: What a New JAMA Pediatrics Study Means for Litigators

Alberto Augsten, PharmD, MS, BCPP, DABAT | Augsten Consulting, LLC

A new research letter in JAMA Pediatrics (Kleinman et al., March 2026) compared buprenorphine-naloxone and methadone for opioid overdose prevention in Ontario youths aged 15 to 24 with opioid use disorder (OUD). The findings, and the published responses they generated, carry direct implications for cases involving adolescent overdose, prescribing-standard disputes, and medical negligence claims tied to substance use disorder treatment.

What the study found

Over one year of follow-up, youths initiated on buprenorphine-naloxone had a 16% reduced hazard of opioid overdose compared with those initiated on methadone. The confidence intervals crossed the null, so the primary outcome was not statistically significant. However, eight deaths occurred during methadone treatment compared with zero during buprenorphine-naloxone treatment — a striking mortality signal in a relatively short observation window.

Two structural features of the cohort matter for litigators: Adolescents 18 and under represented only 2.7% of the study population. The data reflect a Canadian publicly funded system, where access barriers differ meaningfully from those in U.S. private and Medicaid markets.

The labeling issue attorneys should know

A companion analysis published in Cureus (Babul et al., May 2026) flagged a propagated error in widely cited guidelines: buprenorphine is not FDA-approved for OUD in patients under 16. The ASAM 2020 National Practice Guideline states the medication is "approved by the FDA for the treatment of patients aged 16 years and older" — a misstatement that has since appeared in derivative clinical guidance and secondary sources.

This distinction is important in any case where a prescribing-standard or off-label-use argument is raised. The drug is routinely used in adolescent OUD treatment, but the regulatory status and the clinical consensus are not identical, and that gap can become a focal point of expert disagreement.

A widening access disparity

Independent data cited in the response letters describe a pattern that should be familiar to any attorney working overdose litigation: Buprenorphine treatment rose more than threefold among adults over 55 between 2007 and 2018, while declining among youth under 18 (Schuler et al., 2023). TEDS data show MOUD was planned at admission for 93% of adults 25 and older, 56% of those 18 to 24, and only 2% of youth 12 to 17 (Welsh et al., 2022).

In wrongful-death and malpractice matters involving adolescent overdose, these figures support arguments about deviation from a reasonable standard of care when MOUD is not offered, considered, or documented.

Extended-release formulations and the diversion question

The response letters also raise extended-release buprenorphine as the more practical adolescent option, citing reduced diversion risk and improved adherence relative to daily transmucosal dosing. The NIH-funded ERA trial (CTN 0158) is currently evaluating ER versus sublingual buprenorphine in patients aged 14 to 21, notably without a placebo or detoxification arm — a design choice reflecting the position that withholding MOUD from adolescents is no longer ethically defensible.

For litigators, this matters in two ways. First, it shapes the future standard-of-care landscape. Second, in cases where diversion is alleged or implied, the formulation prescribed becomes a relevant fact pattern, not an afterthought.

Takeaways for counsel

The Kleinman study is not definitive, but the combined record — the mortality signal, the under-enrollment of minors, the labeling confusion, and the documented under-treatment of adolescents — gives expert witnesses substantial material to work with on both sides of an OUD-related claim. Cases involving adolescent overdose deaths, MOUD prescribing decisions, or alleged failures to initiate treatment increasingly require an expert who can speak to the pharmacology, the regulatory nuance, and the evolving standard of care in the same testimony.

Alberto Augsten, PharmD, MS, BCPP, DABAT, is a forensic toxicologist and board-certified psychiatric pharmacist providing expert witness consultation in opioid, psychopharmacology, and

References

Kleinman, R. A., Larney, S., Sule, N. O., Ma, C., Szatmari, P., & Kurdyak, P. (2026). Comparative effectiveness of buprenorphine-naloxone and methadone for opioid overdose among youths. JAMA Pediatrics, 180(5), 577–579. https://doi.org/10.1001/jamapediatrics.2026.0041

Babul, A., Ashraf, S., Elmes, R., & Mahdavi, P. (2026). Epistemic barriers to buprenorphine access for adolescents with opioid use disorder. Cureus, 18(5), e108824. https://doi.org/10.7759/cureus.108824

Crotty, K., Freedman, K. I., & Kampman, K. M. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine, 14(2S Suppl 1), 1–91. https://doi.org/10.1097/ADM.0000000000000633

Schuler, M. S., Saloner, B., Gordon, A. J., Dick, A. W., & Stein, B. D. (2023). National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018. Substance Abuse, 44(3), 154–163. https://doi.org/10.1177/08897077231179576

Welsh, J. W., Dennis, M. L., Funk, R., Mataczynski, M. J., & Godley, M. D. (2022). Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults. Journal of Substance Abuse Treatment, 132, 108584. https://doi.org/10.1016/j.jsat.2021.108584